Summit Therapeutics CEO Robert Duggan filed a massive $50M stock purchase on June 12. He bought 3.81 million SMMT shares at around $13.13 each. That same week, President Maky Zanganeh added $1.46M in shares. CFO Manmeet Soni also bought in, spending $722,000 across two transactions. All three executives filed their purchases on or before June 12. The coordinated buying across the C-suite signals strong internal confidence in the biotech's pipeline.
At RYAN (Ryan Specialty Holdings), five insiders filed purchases between June 3 and June 15. Founder and Executive Chairman Patrick Ryan led the charge. He filed a $3.9M purchase of 120,000 shares on June 8. The CFO, General Counsel, and two directors all added smaller positions. The breadth of buying — spanning the chairman, finance chief, and board members — stands out as a rare show of unanimous insider conviction.
Hedge fund Voss Capital, a 10% owner of PAR Technology, filed over $3.7M in open-market purchases on June 15. The fund bought shares across six separate tranches on June 11 and 12. A PAR director also filed a $197,000 purchase on June 15.
Across all three names, no insider selling was reported in the same period — a clean bullish signal from those with the best view of the business.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
